Clinical Trial Update: NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and Neuroenhancement [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the NT-501 CNTF implant for safety, neuroprotection, and neuroenhancement in glaucoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Open-angle Glaucoma

Drugs mentioned

• NT-501 CNTF implant (CNTF implant)

Snippet

Sponsor: Jeffrey L Goldberg | Conditions: Glaucoma, Primary Open Angle | Phase 1 | Status: COMPLETED